» Articles » PMID: 29966171

Risk Factors for Pleural Effusion Recurrence in Patients with Malignancy

Abstract

Background And Objective: The main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE.

Methods: Retrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause-specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine-Gray subdistribution hazard model, and externally validated the model.

Results: A total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X-ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21-2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43-3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04-1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004-1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43-0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy.

Conclusion: Pleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.

Citing Articles

Lymph nodes rather than pleural metabolic activity in F-FDG PET/CT correlates with malignant pleural effusion recurrence in advanced non-small cell lung cancer.

Jiang Y, Liu T, Xu K, Cheng Q, Lu W, Xie J Transl Lung Cancer Res. 2024; 13(9):2236-2253.

PMID: 39430341 PMC: 11484712. DOI: 10.21037/tlcr-24-291.


Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.

Zhang X, Wang X, Wen Y, Chen S, Zhou C, Wu F Clin Transl Med. 2024; 14(4):e1649.

PMID: 38629624 PMC: 11022306. DOI: 10.1002/ctm2.1649.


Trial Protocol: Reaccumulation rate of pleural effusions after therapeutic aspiration: An observational cohort study to determine baseline factors associated with rate of pleural fluid reaccumulation following therapeutic aspiration in patients with....

Mishra E, Clark A, Laskawiec-Szkonter M, Maskell N, Rahman N NIHR Open Res. 2023; 3:5.

PMID: 37881455 PMC: 10593318. DOI: 10.3310/nihropenres.13282.1.


Unraveling the Predictive Potential of Rapid Scoring in Pleural Infection: A Critical Review.

Annareddy Jr S, Ghewade B, Jadhav U, Wagh P Cureus. 2023; 15(9):e44515.

PMID: 37789994 PMC: 10544591. DOI: 10.7759/cureus.44515.


Serum Lactate Dehydrogenase Is a Sensitive Predictor of Systemic Complications of Acute Pancreatitis.

Huang D, Zhong H, Cai Y, Xie W, He X Gastroenterol Res Pract. 2022; 2022:1131235.

PMID: 36329782 PMC: 9626216. DOI: 10.1155/2022/1131235.


References
1.
Austin P, Lee D, Fine J . Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation. 2016; 133(6):601-9. PMC: 4741409. DOI: 10.1161/CIRCULATIONAHA.115.017719. View

2.
Shafiq M, Frick K, Lee H, Yarmus L, Feller-Kopman D . Management of Malignant Pleural Effusion: A Cost-Utility Analysis. J Bronchology Interv Pulmonol. 2015; 22(3):215-25. DOI: 10.1097/LBR.0000000000000192. View

3.
Musani A, Haas A, Seijo L, Wilby M, Sterman D . Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration. 2005; 71(6):559-66. DOI: 10.1159/000081755. View

4.
Lau B, Cole S, Gange S . Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009; 170(2):244-56. PMC: 2732996. DOI: 10.1093/aje/kwp107. View

5.
Boshuizen R, Vincent A, van den Heuvel M . Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion. Support Care Cancer. 2013; 21(11):3109-16. DOI: 10.1007/s00520-013-1895-3. View